A detailed history of Price T Rowe Associates Inc transactions in Vericel Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 27,280 shares of VCEL stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,280
Previous 25,559 6.73%
Holding current value
$1.23 Million
Previous $911,000 55.87%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$32.52 - $52.33 $55,966 - $90,059
1,721 Added 6.73%
27,280 $1.42 Million
Q4 2023

Feb 14, 2024

BUY
$30.85 - $37.09 $5,244 - $6,305
170 Added 0.67%
25,559 $911,000
Q3 2023

Nov 14, 2023

BUY
$31.69 - $39.25 $86,989 - $107,741
2,745 Added 12.12%
25,389 $852,000
Q2 2023

Aug 14, 2023

BUY
$29.0 - $38.37 $16,327 - $21,602
563 Added 2.55%
22,644 $851,000
Q1 2023

May 15, 2023

BUY
$23.85 - $31.34 $20,081 - $26,388
842 Added 3.96%
22,081 $648,000
Q4 2022

Feb 14, 2023

BUY
$17.65 - $27.37 $10,519 - $16,312
596 Added 2.89%
21,239 $559,000
Q3 2022

Nov 14, 2022

BUY
$22.62 - $32.54 $70,054 - $100,776
3,097 Added 17.65%
20,643 $479,000
Q2 2022

Aug 15, 2022

SELL
$22.88 - $39.45 $52,784 - $91,011
-2,307 Reduced 11.62%
17,546 $442,000
Q1 2022

May 16, 2022

BUY
$31.69 - $43.29 $50,006 - $68,311
1,578 Added 8.63%
19,853 $759,000
Q4 2021

Feb 14, 2022

SELL
$35.2 - $52.6 $130,908 - $195,619
-3,719 Reduced 16.91%
18,275 $718,000
Q3 2021

Nov 15, 2021

BUY
$46.35 - $59.75 $151,518 - $195,322
3,269 Added 17.46%
21,994 $1.07 Million
Q2 2021

Aug 16, 2021

BUY
$47.2 - $67.81 $35,777 - $51,399
758 Added 4.22%
18,725 $983,000
Q1 2021

May 17, 2021

BUY
$30.93 - $59.48 $555,719 - $1.07 Million
17,967 New
17,967 $998,000

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $2.13B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.